Krystal Biotech, Inc. Lease, Cost
Krystal Biotech, Inc. (KRYS) reported Lease, Cost of $421.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-03
- Krystal Biotech, Inc. lease, cost for the quarter ending 2026-06-30 was $421.00K, a 5.18% decline year-over-year.
- Krystal Biotech, Inc. lease, cost for the quarter ending 2026-03-31 was $474.00K, a 3.27% decline year-over-year.
- Krystal Biotech, Inc. lease, cost for the quarter ending 2025-12-31 was $461.00K, a 26.65% increase year-over-year.
- Krystal Biotech, Inc. lease, cost for the quarter ending 2025-09-30 was $426.00K, a 30.67% increase year-over-year.
- Krystal Biotech, Inc. lease, cost for fiscal 2025 was $1.82M, a 27.72% increase from fiscal 2024.
- Krystal Biotech, Inc. lease, cost for fiscal 2024 was $1.43M, a 20.79% decline from fiscal 2023.
- Krystal Biotech, Inc. lease, cost for fiscal 2023 was $1.80M, a 2.33% increase from fiscal 2022.
- Krystal Biotech, Inc. lease, cost for fiscal 2022 was $1.76M, a 22.51% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $421.00K 10-Q · filed 2026-08-03 | $895.00K 10-Q · filed 2026-08-03 | $1.36M derived: sum of 3 quarters · filed 2026-08-03 | $1.78M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $474.00K 10-Q · filed 2026-05-04 | $935.00K derived: sum of 2 quarters · filed 2026-05-04 | $1.36M derived: sum of 3 quarters · filed 2026-05-04 | $1.80M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $461.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $887.00K derived: sum of 2 quarters · filed 2026-02-17 | $1.33M derived: sum of 3 quarters · filed 2026-08-03 | $1.82M 10-K · filed 2026-02-17 |
| 2025-09-30 | $426.00K 10-Q · filed 2025-11-03 | $870.00K derived: sum of 2 quarters · filed 2026-08-03 | $1.36M 10-Q · filed 2025-11-03 | $1.72M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $444.00K 10-Q · filed 2026-08-03 | $933.00K 10-Q · filed 2026-08-03 | $1.30M derived: sum of 3 quarters · filed 2026-08-03 | $1.62M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $490.00K 10-Q · filed 2026-05-04 | $854.00K derived: sum of 2 quarters · filed 2026-05-04 | $1.18M derived: sum of 3 quarters · filed 2026-05-04 | $1.58M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $364.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $690.00K derived: sum of 2 quarters · filed 2026-02-17 | $1.09M derived: sum of 3 quarters · filed 2026-02-17 | $1.43M 10-K · filed 2026-02-17 |
| 2024-09-30 | $326.00K 10-Q · filed 2025-11-03 | $723.00K derived: sum of 2 quarters · filed 2025-11-03 | $1.06M 10-Q · filed 2025-11-03 | $1.43M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $397.00K 10-Q · filed 2025-08-04 | $736.00K 10-Q · filed 2025-08-04 | $1.10M derived: sum of 3 quarters · filed 2026-02-17 | $1.54M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $339.00K 10-Q · filed 2025-05-06 | $706.00K derived: sum of 2 quarters · filed 2026-02-17 | $1.15M derived: sum of 3 quarters · filed 2026-02-17 | $1.62M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $367.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $808.00K derived: sum of 2 quarters · filed 2026-02-17 | $1.28M derived: sum of 3 quarters · filed 2026-02-17 | $1.80M 10-K · filed 2026-02-17 |
| 2023-09-30 | $441.00K 10-Q · filed 2024-11-04 | $910.00K derived: sum of 2 quarters · filed 2024-11-04 | $1.43M 10-Q · filed 2024-11-04 | $1.82M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | $469.00K 10-Q · filed 2024-08-05 | $990.00K 10-Q · filed 2024-08-05 | $1.38M derived: sum of 3 quarters · filed 2025-02-19 | $1.83M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | $522.00K 10-Q · filed 2024-05-06 | $912.00K derived: sum of 2 quarters · filed 2025-02-19 | $1.36M derived: sum of 3 quarters · filed 2025-02-19 | $1.82M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $390.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $837.00K derived: sum of 2 quarters · filed 2025-02-19 | $1.30M derived: sum of 3 quarters · filed 2025-02-19 | $1.76M 10-K · filed 2025-02-19 |
| 2022-09-30 | $447.00K 10-Q · filed 2023-11-06 | $909.00K derived: sum of 2 quarters · filed 2023-11-06 | $1.37M 10-Q · filed 2023-11-06 | $1.78M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $462.00K 10-Q · filed 2023-08-07 | $920.00K 10-Q · filed 2023-08-07 | $1.34M derived: sum of 3 quarters · filed 2024-02-26 | $1.74M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $458.00K 10-Q · filed 2023-05-08 | $874.00K derived: sum of 2 quarters · filed 2024-02-26 | $1.28M derived: sum of 3 quarters · filed 2024-02-26 | |
| 2021-12-31 | $416.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $820.00K derived: sum of 2 quarters · filed 2024-02-26 | $1.44M 10-K · filed 2024-02-26 | |
| 2021-09-30 | $404.00K 10-Q · filed 2022-11-07 | $1.02M 10-Q · filed 2022-11-07 | ||
| 2020-12-31 | $824.00K 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |